UK Markets open in 3 hrs 20 mins
  • NIKKEI 225

    27,520.98
    -85.48 (-0.31%)
     
  • HANG SENG

    21,356.79
    +73.27 (+0.34%)
     
  • CRUDE OIL

    78.41
    -0.06 (-0.08%)
     
  • GOLD FUTURES

    1,890.90
    +0.20 (+0.01%)
     
  • DOW

    33,949.01
    -207.68 (-0.61%)
     
  • BTC-GBP

    18,686.25
    -665.98 (-3.44%)
     
  • CMC Crypto 200

    519.70
    -17.19 (-3.20%)
     
  • Nasdaq

    11,910.52
    -203.27 (-1.68%)
     
  • ^FTAS

    4,322.83
    +12.96 (+0.30%)
     

With Humana Inc. (NYSE:HUM) It Looks Like You'll Get What You Pay For

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 14x, you may consider Humana Inc. (NYSE:HUM) as a stock to avoid entirely with its 24.7x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.

Humana could be doing better as it's been growing earnings less than most other companies lately. One possibility is that the P/E is high because investors think this lacklustre earnings performance will improve markedly. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

See our latest analysis for Humana

pe
pe

Want the full picture on analyst estimates for the company? Then our free report on Humana will help you uncover what's on the horizon.

How Is Humana's Growth Trending?

There's an inherent assumption that a company should far outperform the market for P/E ratios like Humana's to be considered reasonable.

Retrospectively, the last year delivered a decent 7.0% gain to the company's bottom line. The latest three year period has also seen a 17% overall rise in EPS, aided somewhat by its short-term performance. So we can start by confirming that the company has actually done a good job of growing earnings over that time.

Looking ahead now, EPS is anticipated to climb by 17% per annum during the coming three years according to the analysts following the company. With the market only predicted to deliver 9.1% per year, the company is positioned for a stronger earnings result.

With this information, we can see why Humana is trading at such a high P/E compared to the market. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

The Final Word

Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

We've established that Humana maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected. At this stage investors feel the potential for a deterioration in earnings isn't great enough to justify a lower P/E ratio. Unless these conditions change, they will continue to provide strong support to the share price.

Having said that, be aware Humana is showing 1 warning sign in our investment analysis, you should know about.

If you're unsure about the strength of Humana's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here